Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $32.00 at Piper Sandler

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price objective reduced by Piper Sandler from $36.00 to $32.00 in a research note released on Friday,Benzinga reports. Piper Sandler currently has a neutral rating on the stock.

Separately, Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $28.29 on Friday. The stock’s fifty day moving average price is $31.91 and its two-hundred day moving average price is $40.57. Amphastar Pharmaceuticals has a one year low of $25.89 and a one year high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market cap of $1.35 billion, a PE ratio of 9.43, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77.

Insider Activity

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 27.10% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Pacer Advisors Inc. increased its stake in shares of Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Amphastar Pharmaceuticals by 9.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company’s stock valued at $44,503,000 after purchasing an additional 105,288 shares during the last quarter. Boston Trust Walden Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after acquiring an additional 439,281 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock valued at $44,674,000 after acquiring an additional 14,015 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 5.1% during the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company’s stock valued at $22,767,000 after acquiring an additional 29,808 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.